Description
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
PHASE II RECRUITMENT IS NOW OPEN
This trial is availableat multiple Sutter locations. Please contact one of the following about the study:
Site Point of Contacts
Alta Bates (CA164)
Painte’ Berniard Piante.Berniard@sutterhealth.org
California PacificMedical Center (CA222)
Sophia Vu (Manager) Sophia.Vue@sutterhealth.org
Eden MedicalCenter (CA200)
Leah Galvez Leah.Galvez@sutterhealth.org
Mills HealthCenter (CA209)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
Memorial MedicalCenter (CA182)
Kristen Moorman Kristen.Moorman@sutterhealth.org
Palo Alto MedicalFoundation (PAMF – All sites)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
SIMR SutterInstitute for Medical Research (SIMR – All sites)
Kirsten Babski Kirsten.Babski@sutterhealth.org
Sutter Cancer Research Consortium
NCIClinicalTrials@sutterhealth.org